Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

BACKGROUND: The present COVID-19 pandemic has tended toward normality. To provide convenient, safe, and effective home treatment programs for patients with recurrent ovarian cancer (ROC), the clinical efficacy and safety of poly (ADP-ribose) polymerase inhibitor (PARPi) (including olaparib, nirapari...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hongmei, Wu, Meng, Liu, Haonan, Zhou, Hang, Zhao, Yang, Geng, Yifan, Jiang, Bo, Zhang, Kai, Zhang, Bo, Han, Zhengxiang, Du, Xiuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652073/
https://www.ncbi.nlm.nih.gov/pubmed/34900739
http://dx.doi.org/10.3389/fonc.2021.785102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652073/
https://www.ncbi.nlm.nih.gov/pubmed/34900739
http://dx.doi.org/10.3389/fonc.2021.785102

Ejemplares similares